Avid Bioservices Inc (CDMO)

[bimerkjaere]

Yes, my chance of being below $1 at year-end (30%, vs. 70% of above $9) is based on bavi's clinical fate alone. If Cotara would be partnered and brought into Ph III, then that should keep prices above $2-$3 IMO.

The imaging potential of the PS program is interesting, but this is a long way from impacting pphm's top-line. Consensus analysts I have seen give 0 value (in terms of valuation) to programs pre-Ph II due to low rate of commercial success.